Hexima Limited. (ASX:HXL)


right-arrow Created with Sketch. 0.005 (1.47%)
MCAP $52.21M
Last trade 10.08am 30/11/2021 20mins delayed

Latest Announcements

26/11/2021HXLHexima Limited.
26/11/2021 Price SensitivePSHXLHexima Limited.
12/11/2021HXLHexima Limited.
08/11/2021HXLHexima Limited.
05/11/2021HXLHexima Limited.
04/11/2021HXLHexima Limited.
01/11/2021HXLHexima Limited.
01/11/2021HXLHexima Limited.

Company Overview

Hexima Limited is an Australia-based clinical stage biotechnology company. The Company is engaged in the research and development of defensin peptides for applications as human therapeutics. The Company’s lead product candidate, pezadeftide applied in a topical formulation, is a potential new prescription treatment for toenail fungal infections or onychomycosis. pezadeftide is under Australian Phase IIb clinical trial. It develops for the treatment of onychomycosis. The Company holds granted, long-life patents protecting pezadeftide in markets globally.

HXL in the news

Biotechnology company Hexima (HXL) successfully completes its share purchase plan (SPP) and…

Search Previous Announcements